Indometacinum
This medicine should always be used exactly as described in the patient leaflet or as directed by your doctor or pharmacist.
ELMETACIN contains indomethacin, which has anti-inflammatory and analgesic properties and belongs to the group of nonsteroidal anti-inflammatory and analgesic drugs.
Indications for use
For symptomatic, local use in the treatment of pain caused by:
If there is no improvement after 3 days or the patient feels worse, they should consult their doctor.
Children and adolescents: ELMETACIN should not be used in children and adolescents, as there is insufficient data on the use of the medicine in this age group. Care should be taken to ensure that children do not touch any area of the body where the spray has been applied.
The eyes should be protected from exposure to the medicine.
In the first and second trimester of pregnancy and during breastfeeding, the medicinal product ELMETACIN may be used only if there are significant indications for such therapy, as prescribed by a doctor.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
After local use in accordance with the recommendations, no interactions with other medicines have been found.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
In the first and second trimester of pregnancy, ELMETACIN can be used only after consulting a doctor.
In the third, final trimester of pregnancy, ELMETACIN should not be used.
Indomethacin, the active ingredient of ELMETACIN, passes into breast milk in small amounts.
During breastfeeding, if possible, the patient should avoid applying the medicine to large areas of skin or using it for an extended period. To avoid direct contact between the child and ELMETACIN, the spray should not be applied to the breast during breastfeeding.
There is no data on the effect of the medicine on the ability to drive and use machines.
This medicine should always be used exactly as described in the patient leaflet or as directed by your doctor or pharmacist. If you are unsure, you should consult your doctor or pharmacist.
Recommended dose
ELMETACIN is applied 3 to 5 times a day. Depending on the size of the painful area, 0.5-1.5 ml of ELMETACIN spray should be applied, e.g., the pump should be pressed 4-12 times (4-12 mg of indomethacin). ELMETACIN should be sprayed onto the affected area so that it is completely covered. The total daily dose should not exceed 7.5 ml of ELMETACIN solution (which corresponds to 60 mg of indomethacin and 60 pump actuations).
The medicine is intended for local use on the skin only. Do not use orally!
The spray should be applied directly to the affected areas without massaging it into the skin. Before the first use, and also after a longer period of non-use, the pump should be pressed several times. Only after such preparation is the container ready for use.
Before applying a dressing, you should wait a few minutes until the skin is dry. It is not recommended to use under an occlusive dressing.
The doctor will decide how long to use the medicine. Usually, treatment for about 1 to 2 weeks is sufficient. No benefits have been established for longer treatment.
If a higher dose of ELMETACIN than recommended has been used, the medicine should be removed from the skin and the skin should be washed with water.
Excessive application of the spray may affect blood clotting.
In case of significant overdose or accidental oral ingestion of ELMETACIN, you should contact your doctor. Depending on the type of symptoms, the doctor will decide what treatment to use.
A double dose should not be used to make up for a missed dose.
If you have any further doubts about the use of this medicine, you should consult your doctor or pharmacist.
Like all medicines, ELMETACIN can cause side effects, although not everybody gets them.
The following classification of frequency of occurrence has been used to evaluate side effects:
Very common: more than 1 in 10 treated patients
Common: more than 1 in 100 treated patients
Uncommon: more than 1 in 1,000 treated patients
Rare: more than 1 in 10,000 treated patients
Very rare: less than 1 in 10,000 treated patients
If side effects occur, the use of ELMETACIN should be stopped, and a doctor should be consulted. If these are symptoms or an allergic reaction, treatment should be stopped and ELMETACIN should never be used again.
If you experience any side effects, including any possible side effects not listed in the leaflet, you should tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department for Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help provide more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Store at a temperature below 25°C.
The solution contains isopropyl alcohol, which is a flammable substance!
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Shelf life after first opening the bottle: 12 months.
Medicines should not be disposed of via wastewater or household waste containers. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of ELMETACIN is indomethacin. 1 g of solution contains 10 mg of indomethacin. 1 ml (0.8 g) of solution contains 8 mg of indomethacin.
The other ingredients are: isopropyl alcohol, isopropyl myristate.
White HDPE bottle with a colorless protective cap made of PP and a pump made of PP, PE, and stainless steel, in a cardboard box.
Packaging: 100 ml.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Stada Arzneimittel AG
Stadastrasse 2-18
D-61118 Bad Vilbel
Germany
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
Mobilat Produktions GmbH
Luitpoldstrasse 1
82576 Pfaffenhofen
Germany
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in the Czech Republic, the country of export: 29/197/87-C
Parallel import authorization number: 433/19
The spray container works completely mechanically (it is not harmful to the environment).
Before the first spraying or if a long period of time has passed since the last use, the pump should be pressed several times, then the spray container will be ready for use.
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.